SciSparc  (NASDAQ:SPRC), a clinical-stage pharmaceutical company that uses cannabis for various treatment modalities, has started a clinical trial for cannabis-based drug SCI-210 aimed at treating symptoms of autism spectrum disorder (ASD) or autism spectrum disorder in children.